XBiotech Faces Uphill Task With Xilonix
Executive Summary
Texas-based biotech XBiotech is going to find it tough to persuade clinicians and regulators about the usefulness of it its human antibody Xilonix after it discontinued the second Phase III study of the human antibody, in US colorectal cancer patients.
You may also be interested in...
XBiotech Says CHMP ‘No’ Was A Surprise, Despite The Signs
Where now for XBiotech? The US firm says that despite a big setback for Xilonix in the EU, it will continue to develop the product in oncology.
Three CHMP Negative Opinions ‒ But Who Got A Boon?
The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.